Thermobalancing conservative treatment for moderate-to-low-degree lower urinary tract symptoms (LUTS) secondary to prostate enlargement

Figures & data

Figure 1. The therapeutic device alone (on the left) and the device tightly applied to the coccyx area in the projection of the prostate.

Figure 2. The changes of urinary symptoms by International Prostate Symptom Score (IPSS) and quality of life (QoL) in 124 patients with BPH on Thermobalancing therapy and in 124 men in the control group at the beginning and at the end of the six-month period.

Figure 3. The changes in prostate volume (PV) ml and uroflowmetry maximum urinary flow rate (Q _max) mL/s in 124 men with BPH on Thermobalancing therapy and in 124 men in the control group at the beginning and at the end of the six-month period.

Table 1. The changes in prostate volume (PV) ml, uroflowmetry (maximum urinary flow rate (Q_max) mL/s and International Prostate Symptom Score (IPSS) in men with BPH and (PV > 60 ml) before and after Thermobalancing therapy

Patient 1, age 73	1 July 2014	3 November 2014
IPSS–Urinary symptoms	14	4
QoL index	4	1
Prostate volume ml	93	70
Q max mL/s	11.2	14.0
Patient 2, age 79	22 July 2014	18 February 2015
IPSS	6	2
QoL index	3	1
Prostate volume ml	154	90
Q max mL/s	13.0	14.4
Patient 3, age 75	3 February 2014	03 November 2014
IPSS–Urinary symptoms	12	3
QoL score	4	0
Prostate volume ml	84	52
Q max mL/s	9.7	15.5
Patient 4, age 73	18 March 2014	10 March 2015
IPSS–Urinary symptoms	16.5	6
QoL score	3	1
Prostate volume ml	74	51
Q max mL/s	7.2	10.3